Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Human Genome Sciences and Kirin announce license agreement

Dec. 4, 2002

Corixa withdraws dispute resolution as FDA returns Bexxar to active review status

Dec. 4, 2002

Telomerase inhibitor with potential as an antitumor and radiosensitizing agent

Dec. 4, 2002

Sulfonyhydrazine prodrug VNP-40101M advances towards phase II clinical evaluation

Dec. 4, 2002

SU-11248: preclinical and early clinical findings encourage further development

Dec. 4, 2002

Improved survival rate found with 131I-ch81C6 in malignant brain tumors

Dec. 4, 2002

Promising toxicity and antitumor efficacy for temozolomide + vatalanib succinate in glioblastoma

Dec. 4, 2002

Aventis claims CDK2 inhibitors for cancer and chemotherapy-induced neuronal apoptosis

Dec. 4, 2002

Celltech presents novel receptor tyrosine kinase inhibitors for cancer, psoriasis, etc.

Dec. 4, 2002

Phase I data demonstrate promising efficacy and safety for oral Raf kinase inhibitor

Dec. 3, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...